Ranibizumab for Radiation Retinopathy

In this interview from ASRS 2018, Dr. Rajiv Anand presents interim results from a randomized trial of ranibizumab, with or without targeted panretinal photocoagulation (tPRP), in patients who develop radiation retinopathy after treatment for uveal melanoma. By 9 months, patients treated with monthly ranibizumab had better visual outcomes than those treated with monthly ranibizumab with tPRP or loading ranibizumab followed by as-needed ranibizumab and tPRP. All 3 groups achieved better visual outcomes than historical Collaborative Ocular Melanoma Study (COMS) controls.

Relevant Financial Disclosures: None